'You lot seem to constantly overlook the extremely low share...

First 8 Last

Share
Profile

Follow
chanstu

99 Posts.

21

03/10/18

09:55

Post #: 35972143
Share

Originally posted by Holla ↑

Of course you took the bait.
A long term relentless downramping non holder who has the majority of their HC posts and time spent on the nor thread, rather than stocks actually held! Nothing suss.
You lot seem to constantly overlook the extremely low share price..
As soon as a 7 figure bank deal hits, wifi/secure credit card/loyalty deal, telco voicemail deal... each app will soon have more than paid for itself, then we can expect things to multiply as further deals eventuate.
The company has everything in place now, and it's only a question of how soon/how much longer until results are realised.
Until then, the share price remains rock bottom.. but when things happen, all the usual downramping from supposed non holders won't stop the share price.
I expect things to be taking off well before the 26th close date, as soon as this week, or next week.
I believe this raise was obviously earlier than it needed to be (As did even the most negative of daily CR posters). It's 4-6 weeks sooner than it needed to be.
There will be good reason.
The NORR rights seem like they're anticipating them to be traded prior to Oct 19.. will there sudden value in them over the coming fortnight?
Maybe you supposed non holders can try jag son rights/raise!
It is all very interesting.

Expand

'You lot seem to constantly overlook the extremely low share price..'

On the contrary.

Holla, everything that you need to know about this stock is reflected in the 'extremely low share price'.

There is no 'hidden value' there AND The Market knows more than you do.

chanstu

NOR Price at posting: 0.5¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 7 more messages in this thread...

First 8 Last

Add NOR (ASX) to my watchlist

(20min delay)
Last 3.8¢		Change 0.000(0.00%)		Mkt cap ! $18.09M

Open	High	Low	Value	Volume
3.7¢	3.8¢	3.7¢	$108	2.88K

Buyers (Bids)

No.	Vol.	Price($)
3	236234	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	200000	1

View Market Depth

No.	Vol.	Price($)
3	236234	0.030
1	50000	0.029
1	120700	0.028
1	150000	0.027
5	550000	0.026

Price($)	Vol.	No.
0.040	200000	1
0.042	23833	1
0.045	1534501	2
0.046	21759	1
0.055	18199	1

Last trade - 15.33pm 07/10/2024 (20 minute delay)

NOR (ASX) Chart

'You lot seem to constantly overlook the extremely low share...

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

'You lot seem to constantly overlook the extremely low share...

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News